RXII Insider Trading Activity and SEC Form 4 Filings
RXII insider trading summary
No open-market insider purchases or sales of RXi Pharmaceuticals Corp (RXII) have been reported on SEC Form 4 in the past 12 months.
Latest RXII insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 2, 2017 | Geert Cauwenbergh | President & CEO | Buy | $92 (200 @ $0.46) |
| Oct 2, 2017 | Geert Cauwenbergh | President & CEO | Buy | $1K (2,700 @ $0.44) |
| Oct 2, 2017 | Geert Cauwenbergh | President & CEO | Buy | $3K (7,100 @ $0.45) |
| Sep 7, 2017 | Alexey Eliseev | Chief Business Officer | Sell | $31K (58,712 @ $0.53) |
| Sep 6, 2017 | Alexey Eliseev | Chief Business Officer | Sell | $49K (91,907 @ $0.54) |
| Sep 5, 2017 | Alexey Eliseev | Chief Business Officer | Sell | $15K (26,181 @ $0.56) |
| Sep 1, 2017 | Alexey Eliseev | Chief Business Officer | Sell | $13K (23,200 @ $0.57) |
| Aug 24, 2017 | Geert Cauwenbergh | President & CEO | Buy | $414 (739 @ $0.56) |
| Aug 24, 2017 | Geert Cauwenbergh | President & CEO | Buy | $3K (4,900 @ $0.55) |
| Aug 24, 2017 | Geert Cauwenbergh | President & CEO | Buy | $2K (4,361 @ $0.55) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.